Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation

NCT01118013 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT01118013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01118013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2010
Completion date
August 31, 2013
Enrollment
6 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma, lymphoproliferative disorder, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms